查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1532236

宠物非处方药市场：2024-2033年全球产业分析、规模、占有率、成长、趋势、预测

OTC Pet Medication Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
出版日期: | 出版商: Persistence Market Research | 英文 300 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research发布了全球宠物非处方药市场的综合报告。本报告深入分析了市场驱动因素、趋势、机会和挑战等关键市场动态，并提供了有关市场结构的详细见解。

关键见解

  • 宠物非处方药市场规模（2024年）：96亿美元
  • 预估市场规模（2033年）：147亿美元
  • 全球市场成长率（2024年至2033年年复合成长率）：4.8%

宠物非处方药市场 - 报告范围：

宠物非处方药市场包括各种目的是治疗和预防宠物常见健康问题的产品。这个市场包括各种治疗方法，包括跳蚤和蜱虫治疗、心臟病药物、止痛药物和营养补充剂。它对应包括狗、猫和其他宠物在内的各个细分市场，并透过宠物商店、线上零售商和兽医医院等管道进行分销。宠物拥有量的增加、人们对宠物健康意识的增强以及对方便易得的治疗方案的偏好推动了市场成长。

推动市场成长的因素：

有几个因素推动全球宠物非处方药市场的发展。宠物拥有率的上升和宠物医疗保健支出的增加，特别是在已开发地区，推动宠物非处方药的需求。药物配方和给药方法的技术进步提高疗效和给药便利性，进一步扩大市场。此外，宠物主人选择预防性护理和非处方治疗来治疗轻微健康问题的趋势也推动了对这些产品的需求。可支配收入的增加和宠物健康意识的提高也促进了市场的成长。

市场限制因素：

儘管成长前景广阔，但宠物非处方药市场仍面临挑战，例如某些药物的高成本以及过敏反应和毒性等潜在副作用。大量提供低价替代品的本地和无组织公司的存在可能会限制知名品牌的市场占有率。此外，严格的宠物药品法规以及不断创新以满足不断变化的宠物健康需求的需求也影响市场。有效的业主教育、有竞争力的定价以及持续的研发投资对于解决这些问题和保持竞争力非常重要。

市场机会：

随着宠物预防保健趋势的不断发展以及人们对宠物健康意识的不断增强，市场存在着巨大的机会。高品质、易于服用的非处方药的开发满足了对有效、便捷的治疗方案日益成长的需求。电子商务平台的扩张提供了新的成长管道，使企业能够接触到更多的人。城市化进程的加速和养宠物家庭数量的增加推动宠物非处方药的需求。策略合作伙伴关係、新技术投资和创新药物配方对于利用新机会和维持市场领先地位非常重要。

本报告涵盖的主要问题

  • 推动全球宠物非处方药市场成长的关键因素是什么？
  • 宠物非处方药的哪些类型和应用在各个宠物领域处于领先地位？
  • 科技进步如何影响宠物非处方药市场的竞争格局？
  • 谁是宠物非处方药市场的主要参与者？
  • 全球宠物非处方药市场的新趋势和未来前景如何？

目录

第1章 执行摘要

第2章 市场概述

  • 市场范围/分类
  • 市场定义/范围/限制

第3章 主要市场趋势

  • 影响市场的主要趋势
    • 世界级的研发推动持续创新
    • 塑造未来的消费趋势
    • 肥胖宠物数量的增加将增加对治疗药物的需求。
    • 宠物人性化促进药品销售
  • 产品创新趋势
  • 宠物非处方药产业的未来展望
    • 推动成长的因素
    • 品牌涌入
    • 创新的经销与行销策略

第4章 全球宠物非处方药市场需求分析

  • 2019-2023年过去的市场数量（单位）分析
  • 2024-2033年当前及未来市场规模（单位）预测
  • 年成长趋势分析

第5章 全球宠物非处方药市场-价格分析

  • 依产品类型进行价格分析
  • 世界平均价格分析基准

第6章 全球宠物非处方药市场需求（金额）分析

  • 2019-2023年市场分析（金额）
  • 2024-2033年市场预测（金额）
    • 年成长趋势分析
    • 绝对的获利机会

第7章 市场背景

  • 宏观经济因素
  • 预测因子 - 相关性和影响
  • 全球宠物非处方药市场PESTLE分析
  • 非处方宠物药品市场投资可行性矩阵
  • 波特对全球宠物非处方药市场的五力分析
  • 市场动态

第8章 依产品类型：世界市场分析

  • 简介/主要发现
  • 2019-2023年市场规模分析（金额）
  • 2024-2033年市场规模分析与预测（金额）
    • 跳蚤和蜱虫
    • 镇痛和关节炎
    • 驱虫药
    • 其他
  • 依产品类型进行市场吸引力分析

第9章 依宠物类型：世界市场分析

  • 简介/主要发现
  • 2019-2023年市场规模分析（价值与数量）
  • 2024-2033年市场规模分析与预测（价值与数量）
    • 狗
    • 猫
    • 鸟类
    • 鱼类和爬虫类
    • 小动物
    • 其他
  • 依宠物类型分析市场吸引力

第10章 依药物剂型：世界市场分析

  • 简介/主要发现
  • 2019-2023年市场规模分析（价值与数量）
  • 2024-2033年市场规模分析与预测（价值与数量）
    • 咀嚼锭和锭剂
    • 胶囊和软膏
    • 喷雾
    • 其他
  • 按剂型分析市场吸引力

第11章 依销售管道：世界市场分析

  • 简介/主要发现
  • 2019-2023年市场规模分析（价值与数量）
  • 2024-2033年市场规模分析与预测（价值与数量）
    • 宠物专卖店
    • 兽医诊所
    • 药局
    • 网路零售
    • 其他
  • 依销售管道分析市场吸引力

第12章 依区域：世界市场分析

  • 简介
  • 2019-2023年市场规模分析（价值与数量）
  • 2024-2033年市场规模分析与预测（价值与数量）
    • 北美
    • 拉丁美洲
    • 欧洲
    • 东亚
    • 南亚
    • 大洋洲
    • 中东和非洲（中东、非洲）
  • 区域市场吸引力分析

第13章 北美宠物OTC药品市场分析

第14章 拉丁美洲宠物非处方药市场分析

第15章 欧洲宠物非处方药市场分析

第16章 南亚宠物OTC药品市场分析

第17章 东亚宠物非处方药市场分析

第18章 大洋洲宠物OTC药品市场分析

第19章 中东及非洲宠物非处方药市场分析

第20章 2024年主要国家宠物非处方药市场分析

  • 简介
    • 主要国家市值比例分析
    • 世界与国家成长比较
  • 美国宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 加拿大宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 墨西哥宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 巴西宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 德国宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 义大利宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 英国宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 中国宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 日本宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 韩国宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 印度宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 澳洲和纽西兰宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道
  • 南非宠物非处方药市场分析
    • 依产品类型
    • 依宠物类型
    • 依药物剂型
    • 依销售管道

第21章 市场结构分析

  • 依公司层级的市场分析（宠物非处方药）
  • 市场集中度
  • 主要公司市占率分析
  • 市场现况分析

第22章 竞争分析

  • 竞争仪表板
  • 有竞争力的价格分析
  • 竞争基准
  • 竞争详情
    • Bayer Companion Animal
    • Boehringer Ingelheim
    • Animal Health
    • Ceva Sante Animate
    • Merck Inc.
    • Zoetis Inc.
    • Elanco
    • Virbac SA
    • Vetoquinol SA
    • Frontline
    • Zymox
    • ChloraSeb
    • Sulfox
    • Adequan
    • Dechra Pharmaceuticals PLC
    • Nutramax Laboratories, Inc.
    • 其他参与者（依要求）

第23章 使用的先决条件与缩写

第24章 研究方法

简介目录
Product Code: PMRREP31512

Persistence Market Research has recently released a comprehensive report on the global OTC Pet Medication Market. This report provides a thorough analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market structure.

Key Insights:

  • OTC Pet Medication Market Size (2024E): USD 9.60 Bn
  • Projected Market Value (2033F): USD 14.7 Bn
  • Global Market Growth Rate (CAGR 2024 to 2033): 4.8%

OTC Pet Medication Market - Report Scope:

The OTC Pet Medication Market includes a wide array of products designed for the treatment and prevention of common health issues in pets. This market covers various medications such as flea and tick treatments, heartworm medications, pain relief, and nutritional supplements. It serves different segments including dogs, cats, and other pets, and is distributed through channels like pet stores, online retailers, and veterinary clinics. Market growth is driven by increasing pet ownership, heightened awareness of pet health, and a preference for convenient and accessible treatment options.

Market Growth Drivers:

Several factors drive the global OTC Pet Medication Market. Rising pet adoption rates and increased spending on pet healthcare, especially in developed regions, boost the demand for OTC pet medications. Technological advancements in medication formulations and delivery methods improve effectiveness and ease of administration, further expanding the market. Additionally, the trend of pet owners opting for preventive care and over-the-counter treatments for minor health issues fuels the demand for these products. Higher disposable income and a focus on pet wellness also contribute to market growth.

Market Restraints:

Despite promising growth prospects, the OTC Pet Medication Market faces challenges such as the high cost of certain medications and potential side effects like allergic reactions and toxicity. The presence of numerous local and unorganized players offering lower-cost alternatives can limit market share for established brands. Additionally, stringent regulations on pet medications and the need for continuous innovation to meet evolving pet health needs impact the market. Effective pet owner education, competitive pricing, and ongoing investment in research and development are essential to address these issues and maintain a competitive edge.

Market Opportunities:

Significant opportunities exist in the market, driven by the rising trend of preventive pet healthcare and increased awareness of pet wellness. Developing high-quality and easy-to-administer OTC medications meets the growing demand for effective and convenient treatment options. The expansion of e-commerce platforms offers new growth channels, allowing companies to reach a broader audience. Increasing urbanization and the rising number of pet-owning households drive the demand for OTC pet medications. Strategic partnerships, investments in new technologies, and innovative medication formulations are crucial for capitalizing on emerging opportunities and maintaining market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the global OTC Pet Medication Market growth?
  • Which types and applications of OTC pet medications are leading adoption in various pet segments?
  • How are technological advancements influencing the competitive landscape of the OTC Pet Medication Market?
  • Who are the key players in the OTC Pet Medication Market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects in the global OTC Pet Medication Market?

Competitive Intelligence and Business Strategy:

Leading players in the global OTC Pet Medication Market, such as Zoetis Inc., Bayer AG, and Elanco Animal Health, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced medication formulations and delivery methods, such as chewable tablets and topical treatments. Collaborations with veterinary clinics, pet health organizations, and online platforms facilitate market access and promote new product adoption. Emphasis on pet owner education, high-quality products, and comprehensive marketing strategies fosters market growth and enhances brand loyalty in the evolving OTC Pet Medication Market landscape.

Key Companies Profiled:

  • Bayer Companion Animal
  • Boehringer Ingelheim
  • Animal Health
  • Ceva Sante Animate
  • Merck Inc.
  • Zoetis Inc.
  • Elanco
  • Virbac SA
  • Vetoquinol SA
  • Frontline
  • Zymox
  • ChloraSeb
  • Sulfox
  • Adequan
  • Dechra Pharmaceuticals PLC

OTC Pet Medication Market by Product Type:

  • Fleas & Ticks
  • Pain Relief & Arthritis
  • Dewormers
  • Others

OTC Pet Medication Market by Pet Type:

  • Dogs
  • Cats
  • Birds
  • Fish & Reptiles
  • Small Pets
  • Others

OTC Pet Medication Market by Medicine Form:

  • Chewable & Tablets
  • Capsules & Ointment
  • Sprays
  • Others

OTC Pet Medication Market by Sales Channel:

  • Pet Specialty Stores
  • Veterinary Clinics
  • Drug & Pharmacy Stores
  • Online Retail
  • Others

OTC Pet Medication Market by Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Overview
  • 1.2. Summary of Key Statistics
  • 1.3. Summary of Key Findings
  • 1.4. Product Evolution Analysis
  • 1.5. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage/Taxonomy
  • 2.2. Market Definition/Scope/Limitations

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
    • 3.1.1. World Class R&D driving Unrelenting Innovation
    • 3.1.2. Consumer Trends Shaping the Future
    • 3.1.3. Rising Number of Obese Pets Boosts the Demand for Therapeutic Offerings
    • 3.1.4. Pet Humanization driving Sales of Medicinal Products
  • 3.2. Product Innovation Trends
  • 3.3. Future Prospects of the OTC Pet Medication Industry
    • 3.3.1. Factors Fuelling the Growth
    • 3.3.2. Influx of Brands
    • 3.3.3. Innovative Distribution and Marketing Strategies

4. Global OTC Pet Medication Market Demand Analysis 2019-2023 and Forecast, 2024-2033

  • 4.1. Historical Market Volume (Units) Analysis, 2019-2023
  • 4.2. Current and Future Market Volume (Units) Projections, 2024-2033
  • 4.3. Y-o-Y Growth Trend Analysis

5. Global OTC Pet Medication Market - Pricing Analysis

  • 5.1. Pricing Analysis By Product Type
  • 5.2. Global Average Pricing Analysis Benchmark

6. Global OTC Pet Medication Market Demand (in Value or Medicine Form in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 6.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 6.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 6.2.1. Y-o-Y Growth Trend Analysis
    • 6.2.2. Absolute $ Opportunity Analysis

7. Market Background

  • 7.1. Macro-Economic Factors
    • 7.1.1. GDP Growth Outlook
    • 7.1.2. Consumer Spending Outlook
    • 7.1.3. GDP Growth Rate Analysis
    • 7.1.4. Internet Penetration Rate Outlook
    • 7.1.5. Income Group Population Overview
    • 7.1.6. Per Capita Disposable Income
  • 7.2. Forecast Factors - Relevance & Impact
    • 7.2.1. Top Companies Historical Growth
    • 7.2.2. Urbanization Growth Outlook
    • 7.2.3. Others
  • 7.3. PESTLE Analysis of Global OTC Pet Medication Market
  • 7.4. Investment Feasibility Matrix of OTC Pet Medication Market
  • 7.5. Porter's Five Forces Analysis of Global OTC Pet Medication Market
  • 7.6. Market Dynamics
    • 7.6.1. Drivers
    • 7.6.2. Restraints
    • 7.6.3. Opportunity Analysis

8. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, By Product Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Product Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product Type, 2024-2033
    • 8.3.1. Fleas & Ticks
    • 8.3.2. Pain Relief & Arthritis
    • 8.3.3. Dewormers
    • 8.3.4. Others
  • 8.4. Market Attractiveness Analysis By Product Type

9. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, by Pet Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) and Volume Analysis By Pet Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) and Volume Analysis and Forecast By Pet Type, 2024-2033
    • 9.3.1. Dogs
    • 9.3.2. Cats
    • 9.3.3. Birds
    • 9.3.4. Fish & Reptiles
    • 9.3.5. Small Pets
    • 9.3.6. Others
  • 9.4. Market Attractiveness Analysis By Pet Type

10. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, by Medicine Form

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) and Volume Analysis By Medicine Form, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) and Volume Analysis and Forecast By Medicine Form, 2024-2033
    • 10.3.1. Chewable & Tablets
    • 10.3.2. Capsules & Ointment
    • 10.3.3. Sprays
    • 10.3.4. Others
  • 10.4. Market Attractiveness Analysis By Medicine Form

11. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, by Sales Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) and Volume Analysis By Sales Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) and Volume Analysis and Forecast By Sales Channel, 2024-2033
    • 11.3.1. Pet Specialty Stores
    • 11.3.2. Veterinary Clinics
    • 11.3.3. Drug & Pharmacy Stores
    • 11.3.4. Online Retail
    • 11.3.5. Others
  • 11.4. Market Attractiveness Analysis By Sales Channel

12. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis by Region, 2019-2023
  • 12.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast by Region, 2024-2033
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis by Region

13. North America OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Pricing Analysis
  • 13.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
  • 13.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
    • 13.4.1. By Country
      • 13.4.1.1. U.S.
      • 13.4.1.2. Canada
    • 13.4.2. By Product Type
    • 13.4.3. By Pet Type
    • 13.4.4. By Medicine Form
    • 13.4.5. Sales Channel
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Country
    • 13.5.2. By Product Type
    • 13.5.3. By Pet Type
    • 13.5.4. By Medicine Form
    • 13.5.5. Sales Channel

14. Latin America OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Pricing Analysis
  • 14.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
  • 14.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
    • 14.4.1. By Country
      • 14.4.1.1. Brazil
      • 14.4.1.2. Mexico
      • 14.4.1.3. Rest of Latin America
    • 14.4.2. By Product Type
    • 14.4.3. By Pet Type
    • 14.4.4. By Medicine Form
    • 14.4.5. Sales Channel
  • 14.5. Market Attractiveness Analysis
    • 14.5.1. By Country
    • 14.5.2. By Product Type
    • 14.5.3. By Pet Type
    • 14.5.4. By Medicine Form
    • 14.5.5. Sales Channel

15. Europe OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Pricing Analysis
  • 15.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
  • 15.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
    • 15.4.1. By Country
      • 15.4.1.1. Germany
      • 15.4.1.2. Italy
      • 15.4.1.3. France
      • 15.4.1.4. U.K.
      • 15.4.1.5. Spain
      • 15.4.1.6. Rest of Europe
    • 15.4.2. By Product Type
    • 15.4.3. By Pet Type
    • 15.4.4. By Medicine Form
    • 15.4.5. Sales Channel
  • 15.5. Market Attractiveness Analysis
    • 15.5.1. By Country
    • 15.5.2. By Product Type
    • 15.5.3. By Pet Type
    • 15.5.4. By Medicine Form
    • 15.5.5. Sales Channel

16. South Asia OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Pricing Analysis
  • 16.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
  • 16.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
    • 16.4.1. By Country
      • 16.4.1.1. India
      • 16.4.1.2. Thailand
      • 16.4.1.3. Indonesia
      • 16.4.1.4. Malaysia
      • 16.4.1.5. Rest of South Asia
    • 16.4.2. By Product Type
    • 16.4.3. By Pet Type
    • 16.4.4. By Medicine Form
    • 16.4.5. Sales Channel
  • 16.5. Market Attractiveness Analysis
    • 16.5.1. By Country
    • 16.5.2. By Product Type
    • 16.5.3. By Pet Type
    • 16.5.4. By Medicine Form
    • 16.5.5. Sales Channel

17. East Asia OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Pricing Analysis
  • 17.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
  • 17.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
    • 17.4.1. By Country
      • 17.4.1.1. China
      • 17.4.1.2. Japan
      • 17.4.1.3. South Korea
    • 17.4.2. By Product Type
    • 17.4.3. By Pet Type
    • 17.4.4. By Medicine Form
    • 17.4.5. Sales Channel
  • 17.5. Market Attractiveness Analysis
    • 17.5.1. By Country
    • 17.5.2. By Product Type
    • 17.5.3. By Pet Type
    • 17.5.4. By Medicine Form
    • 17.5.5. Sales Channel

18. Oceania OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Pricing Analysis
  • 18.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
  • 18.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
    • 18.4.1. By Country
      • 18.4.1.1. Australia
      • 18.4.1.2. New Zealand
    • 18.4.2. By Product Type
    • 18.4.3. By Pet Type
    • 18.4.4. By Medicine Form
    • 18.4.5. Sales Channel
  • 18.5. Market Attractiveness Analysis
    • 18.5.1. By Country
    • 18.5.2. By Product Type
    • 18.5.3. By Pet Type
    • 18.5.4. By Medicine Form
    • 18.5.5. Sales Channel

19. Middle East and Africa OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Pricing Analysis
  • 19.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
  • 19.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
    • 19.4.1. By Country
      • 19.4.1.1. GCC Countries
      • 19.4.1.2. Northern Africa
      • 19.4.1.3. South Africa
      • 19.4.1.4. Rest of Middle East and Africa
    • 19.4.2. By Product Type
    • 19.4.3. By Pet Type
    • 19.4.4. By Medicine Form
    • 19.4.5. Sales Channel
  • 19.5. Market Attractiveness Analysis
    • 19.5.1. By Country
    • 19.5.2. By Product Type
    • 19.5.3. By Pet Type
    • 19.5.4. By Medicine Form
    • 19.5.5. Sales Channel

20. Key Countries' OTC Pet Medication Market Analysis 2024

  • 20.1. Introduction
    • 20.1.1. Market Value Proportion Analysis, By Key Countries
    • 20.1.2. Global Vs. Country Growth Comparison
  • 20.2. U.S. OTC Pet Medication Market Analysis
    • 20.2.1. By Product Type
    • 20.2.2. By Pet Type
    • 20.2.3. By Medicine Form
    • 20.2.4. Sales Channel
  • 20.3. Canada OTC Pet Medication Market Analysis
    • 20.3.1. By Product Type
    • 20.3.2. By Pet Type
    • 20.3.3. By Medicine Form
    • 20.3.4. Sales Channel
  • 20.4. Mexico OTC Pet Medication Market Analysis
    • 20.4.1. By Product Type
    • 20.4.2. By Pet Type
    • 20.4.3. By Medicine Form
    • 20.4.4. Sales Channel
  • 20.5. Brazil OTC Pet Medication Market Analysis
    • 20.5.1. By Product Type
    • 20.5.2. By Pet Type
    • 20.5.3. By Medicine Form
    • 20.5.4. Sales Channel
  • 20.6. Germany OTC Pet Medication Market Analysis
    • 20.6.1. By Product Type
    • 20.6.2. By Pet Type
    • 20.6.3. By Medicine Form
    • 20.6.4. Sales Channel
  • 20.7. Italy OTC Pet Medication Market Analysis
    • 20.7.1. By Product Type
    • 20.7.2. By Pet Type
    • 20.7.3. By Medicine Form
    • 20.7.4. Sales Channel
  • 20.8. U.K. OTC Pet Medication Market Analysis
    • 20.8.1. By Product Type
    • 20.8.2. By Pet Type
    • 20.8.3. By Medicine Form
    • 20.8.4. Sales Channel
  • 20.9. China OTC Pet Medication Market Analysis
    • 20.9.1. By Product Type
    • 20.9.2. By Pet Type
    • 20.9.3. By Medicine Form
    • 20.9.4. Sales Channel
  • 20.10. Japan OTC Pet Medication Market Analysis
    • 20.10.1. By Product Type
    • 20.10.2. By Pet Type
    • 20.10.3. By Medicine Form
    • 20.10.4. Sales Channel
  • 20.11. S. Korea OTC Pet Medication Market Analysis
    • 20.11.1. By Product Type
    • 20.11.2. By Pet Type
    • 20.11.3. By Medicine Form
    • 20.11.4. Sales Channel
  • 20.12. India OTC Pet Medication Market Analysis
    • 20.12.1. By Product Type
    • 20.12.2. By Pet Type
    • 20.12.3. By Medicine Form
    • 20.12.4. Sales Channel
  • 20.13. Australia and New Zealand OTC Pet Medication Market Analysis
    • 20.13.1. By Product Type
    • 20.13.2. By Pet Type
    • 20.13.3. By Medicine Form
    • 20.13.4. Sales Channel
  • 20.14. South Africa OTC Pet Medication Market Analysis
    • 20.14.1. By Product Type
    • 20.14.2. By Pet Type
    • 20.14.3. By Medicine Form
    • 20.14.4. Sales Channel

21. Market Structure Analysis

  • 21.1. Market Analysis by Tier of Companies (OTC Pet Medication)
  • 21.2. Market Concentration
  • 21.3. Market Share Analysis of Top Players
  • 21.4. Market Presence Analysis
    • 21.4.1. By Regional Footprint of Players
    • 21.4.2. Product Footprint by Players
    • 21.4.3. Channel Footprint by Players

22. Competition Analysis

  • 22.1. Competition Dashboard
  • 22.2. Pricing Analysis by Competition
  • 22.3. Competition Benchmarking
  • 22.4. Competition Deep Dive
    • 22.4.1. Bayer Companion Animal
      • 22.4.1.1. Overview
      • 22.4.1.2. Product Portfolio
      • 22.4.1.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.1.4. Sales Footprint
      • 22.4.1.5. Strategy Overview
        • 22.4.1.5.1. Marketing Strategy
        • 22.4.1.5.2. Product Strategy
        • 22.4.1.5.3. Channel Strategy
    • 22.4.2. Boehringer Ingelheim
      • 22.4.2.1. Overview
      • 22.4.2.2. Product Portfolio
      • 22.4.2.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.2.4. Sales Footprint
      • 22.4.2.5. Strategy Overview
        • 22.4.2.5.1. Marketing Strategy
        • 22.4.2.5.2. Product Strategy
        • 22.4.2.5.3. Channel Strategy
    • 22.4.3. Animal Health
      • 22.4.3.1. Overview
      • 22.4.3.2. Product Portfolio
      • 22.4.3.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.3.4. Sales Footprint
      • 22.4.3.5. Strategy Overview
        • 22.4.3.5.1. Marketing Strategy
        • 22.4.3.5.2. Product Strategy
        • 22.4.3.5.3. Channel Strategy
    • 22.4.4. Ceva Sante Animate
      • 22.4.4.1. Overview
      • 22.4.4.2. Product Portfolio
      • 22.4.4.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.4.4. Sales Footprint
      • 22.4.4.5. Strategy Overview
        • 22.4.4.5.1. Marketing Strategy
        • 22.4.4.5.2. Product Strategy
        • 22.4.4.5.3. Channel Strategy
    • 22.4.5. Merck Inc.
      • 22.4.5.1. Overview
      • 22.4.5.2. Product Portfolio
      • 22.4.5.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.5.4. Sales Footprint
      • 22.4.5.5. Strategy Overview
        • 22.4.5.5.1. Marketing Strategy
        • 22.4.5.5.2. Product Strategy
        • 22.4.5.5.3. Channel Strategy
    • 22.4.6. Zoetis Inc.
      • 22.4.6.1. Overview
      • 22.4.6.2. Product Portfolio
      • 22.4.6.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.6.4. Sales Footprint
      • 22.4.6.5. Strategy Overview
        • 22.4.6.5.1. Marketing Strategy
        • 22.4.6.5.2. Product Strategy
        • 22.4.6.5.3. Channel Strategy
    • 22.4.7. Elanco
      • 22.4.7.1. Overview
      • 22.4.7.2. Product Portfolio
      • 22.4.7.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.7.4. Sales Footprint
      • 22.4.7.5. Strategy Overview
        • 22.4.7.5.1. Marketing Strategy
        • 22.4.7.5.2. Product Strategy
        • 22.4.7.5.3. Channel Strategy
    • 22.4.8. Virbac SA
      • 22.4.8.1. Overview
      • 22.4.8.2. Product Portfolio
      • 22.4.8.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.8.4. Sales Footprint
      • 22.4.8.5. Strategy Overview
        • 22.4.8.5.1. Marketing Strategy
        • 22.4.8.5.2. Product Strategy
        • 22.4.8.5.3. Channel Strategy
    • 22.4.9. Vetoquinol SA
      • 22.4.9.1. Overview
      • 22.4.9.2. Product Portfolio
      • 22.4.9.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.9.4. Sales Footprint
      • 22.4.9.5. Strategy Overview
        • 22.4.9.5.1. Marketing Strategy
        • 22.4.9.5.2. Product Strategy
        • 22.4.9.5.3. Channel Strategy
    • 22.4.10. Frontline
      • 22.4.10.1. Overview
      • 22.4.10.2. Product Portfolio
      • 22.4.10.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.10.4. Sales Footprint
      • 22.4.10.5. Strategy Overview
        • 22.4.10.5.1. Marketing Strategy
        • 22.4.10.5.2. Product Strategy
        • 22.4.10.5.3. Channel Strategy
    • 22.4.11. Zymox
      • 22.4.11.1. Overview
      • 22.4.11.2. Product Portfolio
      • 22.4.11.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.11.4. Sales Footprint
      • 22.4.11.5. Strategy Overview
        • 22.4.11.5.1. Marketing Strategy
        • 22.4.11.5.2. Product Strategy
        • 22.4.11.5.3. Channel Strategy
    • 22.4.12. ChloraSeb
      • 22.4.12.1. Overview
      • 22.4.12.2. Product Portfolio
      • 22.4.12.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.12.4. Sales Footprint
      • 22.4.12.5. Strategy Overview
        • 22.4.12.5.1. Marketing Strategy
        • 22.4.12.5.2. Product Strategy
        • 22.4.12.5.3. Channel Strategy
    • 22.4.13. Sulfox
      • 22.4.13.1. Overview
      • 22.4.13.2. Product Portfolio
      • 22.4.13.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.13.4. Sales Footprint
      • 22.4.13.5. Strategy Overview
        • 22.4.13.5.1. Marketing Strategy
        • 22.4.13.5.2. Product Strategy
        • 22.4.13.5.3. Channel Strategy
    • 22.4.14. Adequan
      • 22.4.14.1. Overview
      • 22.4.14.2. Product Portfolio
      • 22.4.14.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.14.4. Sales Footprint
      • 22.4.14.5. Strategy Overview
        • 22.4.14.5.1. Marketing Strategy
        • 22.4.14.5.2. Product Strategy
        • 22.4.14.5.3. Channel Strategy
    • 22.4.15. Dechra Pharmaceuticals PLC
      • 22.4.15.1. Overview
      • 22.4.15.2. Product Portfolio
      • 22.4.15.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.15.4. Sales Footprint
      • 22.4.15.5. Strategy Overview
        • 22.4.15.5.1. Marketing Strategy
        • 22.4.15.5.2. Product Strategy
        • 22.4.15.5.3. Channel Strategy
    • 22.4.16. Nutramax Laboratories, Inc.
      • 22.4.16.1. Overview
      • 22.4.16.2. Product Portfolio
      • 22.4.16.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.16.4. Sales Footprint
      • 22.4.16.5. Strategy Overview
        • 22.4.16.5.1. Marketing Strategy
        • 22.4.16.5.2. Product Strategy
        • 22.4.16.5.3. Channel Strategy
    • 22.4.17. Other Players (As Requested)
      • 22.4.17.1. Overview
      • 22.4.17.2. Product Portfolio
      • 22.4.17.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.4.17.4. Sales Footprint
      • 22.4.17.5. Strategy Overview
        • 22.4.17.5.1. Marketing Strategy
        • 22.4.17.5.2. Product Strategy
        • 22.4.17.5.3. Channel Strategy

23. Assumptions and Acronyms Used

24. Research Methodology